Intranasal Oxytocin for the Treatment of Autism Spectrum Disorders (INOT)
Sponsor: Montefiore Medical Center
Listed as NCT01337687, this NA trial focuses on Autism Spectrum Disorders and remains completed. Sponsored by Montefiore Medical Center, it has been updated 10 times since 2009, reflecting substantial change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Sep 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jan 2023 — Jul 2024 [monthly]
Completed NA
-
Dec 2022 — Jan 2023 [monthly]
Completed NA
▶ Show 5 earlier versions
-
Jan 2021 — Dec 2022 [monthly]
Completed NA
-
Mar 2020 — Jan 2021 [monthly]
Completed NA
-
Jun 2018 — Mar 2020 [monthly]
Completed NA
-
Feb 2017 — Jun 2018 [monthly]
Completed NA
-
Jan 2017 — Feb 2017 [monthly]
Completed NA
First recorded
Oct 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Montefiore Medical Center
- National Alliance for Research on Schizophrenia and Depression
For direct contact, visit the study record on ClinicalTrials.gov .